Intravenous Glycoprotein IIb/IIIa Inhibitor (Tirofiban) followed by Intra-Arterial Urokinase and Mechanical Thrombolysis in Stroke

References

1. 1.↵
   The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587

   CrossRefPubMedWeb of Science
2. 2.↵
   Bourekas EC, Slivka AP, Shah R, et al. Intraarterial thrombolytic therapy within 3 hours of the onset of stroke. Neurosurgery 2004;54:39–46

   PubMedWeb of Science
3. 3.↵
   Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002;59:862–867

   Abstract/FREE Full Text
4. 4.↵
   Del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomised trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke: PROACT Investigators: Prolyse in Acute Cerebral Thromboembolism. Stroke 1998;29:4–11

   Abstract/FREE Full Text
5. 5.↵
   Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003–2011

   CrossRefPubMedWeb of Science
6. 6.↵
   Lewandowsky CA, Frankel M, Tomsick TA, et al. Combined intra-venous and intra-arterial rtPA versus intra-arterial therapy of acute ischemic stroke : Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999;30:2598–2605

   Abstract/FREE Full Text
7. 7.↵
   IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004;35:904–912

   Abstract/FREE Full Text
8. 8.↵
   Lee DH, Jo KD, Kim HG, et al. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. J Vasc Interv Radiol 2002;13:769–723

   CrossRefPubMed
9. 9.
   Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488–1497

   CrossRefPubMedWeb of Science
10. 10.↵
    Straub S, Junghans U, Jovanovic V, et al. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke 2004;35:705–709

    Abstract/FREE Full Text
11. 11.↵
    Eckert B, Koch C, Thomalla G, et al. Acute basilar artery occlusion treated with combined intravenous abciximab and intra-arterial tissue plasminogen activator: report of 3 cases. Stroke 2002;33:1424–1427

    Abstract/FREE Full Text
12. 12.↵
    Cloft HJ, Samuels OB, Tong FC, Dion JE. Use of abciximab for mediation of thromboembolic complications of endovascular therapy. AJNR Am J Neuroradiol 2001;22:1764–1767

    Abstract/FREE Full Text
13. 13.↵
    Barber PA, Demehuk AM, Zhang J, Buchan AM, for the ASPECT Study Group. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy: Alberta Stroke Programme early CT score. Lancet 2000;355:1670–1674

    CrossRefPubMedWeb of Science
14. 14.↵
    Deshmukh VR, Fiorella DJ, Albuquerque FC, et al. Intra-arterial thrombolysis for acute ischemic stroke: preliminary experience with platelet glycoprotein IIb/Iia inhibitors as adjunctive therapy. Neurosurgery 2005;56:46–55

    PubMed
15. 15.↵
    RC Lisboa, BD Jovanovic, MJ Alberts. Analysis of the safety and efficacy of intra-arterial thrombolytic therapy in ischemic stroke. Stroke 2002;33:2866–2871

    Abstract/FREE Full Text
16. 16.↵
    Adams H. Effect of abciximab for acute ischemic stroke: final results of Abciximab in Emergent Stroke Treatment Trial (AbESTT) presented at the 28th International Stroke Conference February 2003. Stroke 2003;34:252
17. 17.↵
    Seitz RJ, Hamzavi M, Junghans U, et al. Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations. Stroke 2003;34:1932–1935

    Abstract/FREE Full Text
18. 18.↵
    Cheung RT, Ho DS. Fatal hemorrhagic transformation of acute cerebral infarction after the use of abciximab. Stroke 2000;31:2526–2527
19. 19.↵
    Qureshi AL, Saad M, Zaidat OO, et al. Intracerebral hemorrhages associated with neurointerventional procedures using a comination of antithrombotic agents including abciximab. Stroke 2002;33:1916–1919

    Abstract/FREE Full Text
20. 20.↵
    Ueda T, Sakaki S, Nochide I, et al Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries. Stroke 1998;29:2568–2574

    Abstract/FREE Full Text
21. 21.↵
    Abumiya T, Fitridge R, Mazur C, et al. Integrin alfa(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral schemia. Stroke 2000 :31 ;1402–1410

    Abstract/FREE Full Text
22. 22.↵
    Fassbender K, Dempfle CE, Mielke O, et al. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke 1999;30:2101–2104

    Abstract/FREE Full Text
23. 23.↵
    Siess W. Molecular mechanisms of platelet activation. Physiol Rev 1989;69:58–178

    FREE Full Text
24. 25.↵
    Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998;97:544–552

    Abstract/FREE Full Text
25. 26.↵
    Junghans U, Seitz RJ, Aulich A, et al. Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study. Cerebrovasc Dis 2001;12:308–312
26. 27.
    Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000;139:S38–S45

    CrossRefPubMedWeb of Science